Newspaper icon
The latest issue of Financial Standard now available as an e-newspaper
READ NOW

Superannuation

Hostplus, HESTA invest in Remedy Robotics

Hostplus and HESTA are part of consortium that helped raised $62 million for healthcare and physical artificial intelligence (AI) company Remedy Robotics.

The Series B raise led by venture capital specialist DCVC was also made in conjunction with UC Investments, the University of California's investment office, Skip Capital and Bioshore Ventures.

This is alongside existing investors Build Collective by Tony Fadell, Blackbird, Divergent Capital and KdT Ventures.

A developer of robotic systems for cardiovascular care and endovascular intervention, Remedy Robotics will use the funds to deliver immediate robotic care to all patients regardless of location.

The funding will support several major milestones, including a planned pivotal clinical trial in partnership with the University of California and advancement toward US Food and Drug Administration (FDA) approval for neurovascular intervention.

Remedy will also deploy prototype N1 Systems across its network of clinical partners, including through its strategic partnerships with SVIN Mission Thrombectomy and the Australian Stroke Alliance, and continue to advance its AI capabilities and autonomous functions.

"Endovascular intervention is the gold standard treatment for stroke and many cardiovascular emergencies, yet access remains limited to a small number of hospitals. For these time-critical conditions, that's devastating. Even when specialist intervention is available, treatment is often delayed, and complications are frustratingly common," Remedy Robotics chief executive and co-founder David Bell said.

"This funding will allow us to accelerate toward deployment of our N1 System so we can bring quality intervention to patients everywhere, regardless of geography."

The N1 System is a robotic platform and software suite that uses machine learning to analyse preoperative imaging, simulate cases in advance, provide real-time 3D-2D image registration and complete entire endovascular procedures robotically.

Headquartered in San Francisco, Remedy Robotics works with more than 100 hospitals worldwide.

Blackbird partner Michael Tolo said: "Remedy is building the kind of company we look for at Blackbird: one with world-class technical talent, a massive global problem to solve, and the potential to create an entirely new category."

"We believe Remedy is uniquely positioned to transform how endovascular care is delivered, and we are excited to support the company through its next phase of growth."

Read more: Remedy Robotics,  Blackbird,  HESTA,  Hostplus,  N1 System,  University of California,  Divergent Capital,  Australian Stroke Alliance,  Bioshore Ventures,  Build Collective,  David Bell,  US Food and Drug Administration,  KdT Ventures,  Michael Tolo,  SVIN Mission Thrombectomy,  Tony Fadell,  UC Investments